Ian has made some good deals for the shareholders In the past so I can't see why he would b3 any different for cxx It is nerve wrecking though
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
